The global market for farm-raised Atlantic salmon and rainbow trout presents a substantial commercial opportunity

BioVaxys and SpayVac for Wildlife Expand License Agreement into Commercial Aquaculture, Targeting Multi-Million Ton Farmed Fish Market

CANADA
Thursday, April 24, 2025, 00:10 (GMT + 9)

Farmed Salmon and Trout Represent Major New Market for SpayVac

BioVaxys Technology Corp. and SpayVac for Wildlife, Inc. have jointly announced a significant expansion of their existing License Agreement's Fields of Use to include the commercial aquaculture and farm-raised fish markets. This strategic move broadens SpayVac-for-Wildlife's market reach, now encompassing its single-dose, no-booster fertility-control vaccines for aquaculture, alongside its applications for overabundant feral, wild, and invasive animals, as well as select production and companion animals. This expansion significantly increases SpayVac’s global revenue potential.

The global market for farm-raised Atlantic salmon and rainbow trout presents a substantial commercial opportunity for SpayVac. According to Seafish, a UK-based public body supporting the aquaculture industry, the annual harvest of these two species alone totals approximately 3.28 million metric tons, estimated to be 800 million individual fish. SpayVac-for-Wildlife CEO Thomas D’Orazio stated, “This represents a considerable addressable market for SpayVac’s contraceptive vaccines, which are being developed as a compelling alternative to triploidy—a genetic manipulation technique commonly used in aquaculture to induce sterility. Requiring only a single administration, SpayVac’s immunocontraceptive approach offers producers a scalable and cost-effective solution for reproductive control in farmed fish, paving the way for significant vaccine sales across the global aquaculture sector.”

Initial proof-of-concept trials in aquaculture are progressing well, and the program has now entered its second phase of development, which focuses on optimizing the injection timing within the fish's life cycle for maximum efficacy.

SpayVac emphasizes that its vaccines achieve infertility in animals with a single-dose formulation. The core of SpayVac’s technology lies in a patented liposome-based delivery platform developed by BioVaxys and licensed to SpayVac. This platform is engineered to create long-lasting and targeted immune responses.

SpayVac has also reportedly begun the regulatory submission process for its initial product targeting feral horse and free-ranging deer populations, with the U.S. Bureau of Land Management (BLM) identified as a potential lead customer for managing these populations.

“We are extremely pleased and excited by the progress of SpayVac-for-Wildlife,” commented BioVaxys President and Chief Operating Officer Kenneth Kovan. “Based on the superior profile of SpayVac vaccines and the significant U.S. market potential with feral horses and deer, we anticipate a healthy royalty revenue stream from SpayVac sales. With substantial global markets for horses and deer, such as Australia, and this expansion into commercial aquaculture, including the vast farm-raised fish market, SpayVac is strategically positioned to become a major player in the animal health field.”

editorial@seafood.media
www.seafood.media

Print